DMAC earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT / 7:00 AM CDT Web access: https://app.webinar.net/nG3yPzRP7wk Dial In: (646)

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 31, 2026 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/bxPLk6nkE0q Dial In: (646) 357-8766 Confe

Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027 Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutica

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 13, 2025 Time: 8:00 AM ET /7:00 AM CT Web access: https://app.webinar.net/MlAxZJky3Q7 Dial In: (888) 880-3330 Conference ID: 9449322

Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Enrollment for ReMEDy2 Phase 2/3 Trial Progressing with Interim Data Anticipated in Q2 2026 Inclusion in the Russell 2000® and 3000® Indexes Appointment of Julie Krop, MD, to Chief Medical Officer Conference Call and Webcast August 13 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, August 13, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/BMb9EBAwZYP Dial In: (800) 836-8184 Con

Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barrier and was Generally Safe and Well Tolerated Highly Statistically Significant Reduction in Uterine Artery Pulsatility Index Robust Evidence Supports a Potential Best-In-Class Mechanism Enhancing Placental Perfusion, Protecting the Endothelium and Reducing Blood Pressure DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Par

Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025 KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study Design Acute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as Planned Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended M

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 18, 2025 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/yzor97w9Nvj Dial In: (800) 836-8184 Conference ID: 50034 Interested parties may access the conference call

Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf

Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, A

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2024 financial results will be released after the markets close on Wednesday, August 7th. DiaMedica will host a live conference call on Thursday, August 8th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, August 8, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/RzlwnM9ne8E Dial In: (646) 357-8785 Conference

 Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Discuss Preeclampsia Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclamp

Conference Call and Webcast May 9 at 8:00 AM Eastern Time / 7:00 AM Central Time  First Patient Dosed in Relaunch of ReMEDy2 Stroke Trial Clinical Operations Team Expanded to Support Global Expansion $46.5 Million Cash with Runway to 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024. Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial resul

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.   Conference Call details:   Date: Thursday, May 9, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/jDdlnVm9Ewq Dial In: (646) 357-8785 Conf

Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023. Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full

Conference Call and Webcast November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Updated Amendment to Phase 2/3 ReMEDy2 AIS Protocol Aimed at Enhancing Patient Enrollment and Increasing Probability of Study Success, 30-Day FDA Review Period Passed Without Comment ReMEDy2 Initial Activation of Clinical Sites Expected in November and December $56 Million Cash with Runway to 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023. Management will host a con

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13th. DiaMedica will host a live conference call on Tuesday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, November 14, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/OVpdLmgYMDE Dial In: (877) 550-1858 Conferen

Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M "At-The-Market" Private Placement, Cash Runway Into 2026 Company Completed an Additional Safety Cohort of ACEi Patients in its Phase 1C Healthy Volunteer Study DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023. Management will host a conference call Tuesday, August 15, 2023, at 7:00AM Cent

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, August 15, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/DnqEQYkbk6Z Dial In: (877) 550-1858 Conference ID

Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV Dose of 0.5 µg/kg for Continuing the ReMEDy2 Trial DiaMedica Plans to File Complete Clinical Hold Response This Week Cash Runway Into Q4 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2023. Manage

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, May 16, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/r4298p1YBXV Dial In: (877) 550-1858 Conference ID: 21

Conference Call and Webcast March 29 at 8:00 am Eastern Time / 7:00 am Central Time Company has had Ongoing and Successful Communications with the FDA to Address the Clinical Hold Company Completed Part 1 of In-Use Study, Results Support Proposed ReMEDy2 Dose Revision Cash Runway into Q4 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022. Management will host a conference call Wednesday, March 29, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to d

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, March 29, 2023 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/OZWB76e3RGX Dial In: (877) 550-1858 Conference ID: 1754341 Interested

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its ReMEDy2 Phase 2/3 trial for the treatment of acute ischemic stroke (AIS). The FDA stated it is maintaining its clinical hold at this time and that additional non-clinical data related to the materials used by a hospital in the IV infusion process is needed to resolve the clinical hold. In response to the FDA's clinical hold letter in July 2022 related to three serious adverse

 Conference Call and Webcast August 11 at 8:00 am Eastern Time / 7:00 am Central Time  Company Confident in Plan to Resolve Issues that Led to Clinical Hold of Phase 2/3 ReMEDy2 Trial Proposal to Resume Trial Will be Submitted to FDA in September Cash Runway Into 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended June 30, 2022. DiaMedica will host a conference call on Thursday, August 11, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th. DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, August 11, 2022 Time: 7:00 AM CT / 8:00 AM ET Web access: https://events.q4inc.com/attendee/328637791 Dial In: (888) 440-4368 Conference ID: 4814247 Interested

Conference Call and Webcast May 5 at 8:00 am Eastern Time / 7:00 am Central Time Continuing to Expand Clinical Study Sites in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Cash Runway Into 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022. DiaMedica will host a conference call on Thursday, May 5, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and first quarter financial results. Clinical Developments DM199 for the

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th. DiaMedica will host a live conference call on Thursday, May 5th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details:   Date:   Thursday, May 5, 2022 Time:   7:00 AM CT / 8:00 AM ET Web access:   https://events.q4inc.com/attendee/640421392 Dial In:   (888) 440-4368 Conference ID:   4814247 Int

Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Team Expanded with Addition of Chief Medical Officer and Chief Commercial Officer Strong Balance Sheet with $45M Cash, Runway Into 2024 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the year ended December 31, 2021. Management will host a conference call Tuesday, March 15, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14th. DiaMedica will host a live conference call on Tuesday, March 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 15, 2022 Time: 7:00 AM CT / 8:00 AM ET Web access: https://events.q4inc.com/attendee/778628289 Dial In: (888) 440-4368 Conference ID: 4814247 Interested parties

Conference Call and Webcast November 11 at 8:00 am Eastern Time / 7:00 am Central Time First Patient Dosed in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke FDA Accepts ReMEDy2 Protocol Amendment Elevating Stroke Recurrence to Primary Endpoint Balance Sheet Strengthened with $30 Million Private Placement DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended September 30, 2021. Management will host a conferen

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third quarter 2021 financial results will be released after the markets close on Wednesday, November 10th. DiaMedica will host a live conference call on Thursday, November 11th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call details: Date: Thursday, November 11, 2021 Time: 7:00 AM CT / 8:00 AM ET Web access: https://events.q4inc.com/attendee/250819405 Dial In: (888) 440-4368 Conference ID: 4814247 Interested

Phase 2/3 ReMEDy2 Trial in AIS for Stroke Outcomes and Stroke Recurrence on Track for Initiation Summer 2021 Positive REDUX Phase 2 Interim Data Announced for CKD: IgA Nephropathy Data Indicate Statistically & Clinically Significant 33% Reduction in Albuminuria (UACR). Board of Directors Strengthened with Election of Two Pharma Industry Veterans  Conference Call and Webcast August 12 at 8:00 am Eastern Time / 7:00 am Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 3

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August 11th. DiaMedica will host a live conference call on Thursday, August 12th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call details: Date: Thursday, August 12, 2021 Time: 7:00 AM CT / 8:00 AM ET Web access: https://event.on24.com/wcc/r/3192933/FBC5C2BE41E26E2C70F89B28EC5DB100 Dial In: (844) 557-8483 (domestic) (825) 31